Draig Therapeutics

Draig, meaning 'dragon,' aims to improve brain health through new treatments inspired by its mission to serve communities.

DT-101 is an AMPA receptor modulator designed to restore synaptic connections in major depressive disorder (MDD) with a favorable safety profile.

Todd D. Gould , Sanjay J. Mathew, Maurizio Fava, and Anantha Shekhar

Ivana is President and Chief Executive Officer of Draig Therapeutics. She is an accomplished pharmaceutical and biotechnology executive with over 25 years of senior management experience, leading companies across a wide range of strategic and operational functions.

Draig’s pipeline of AMPA and GABAA receptor modulators aims to safely and precisely modulate circuits linked to neuropsychiatric disorders.

Draig Therapeutics develops neuropsychiatric therapies using neuromodulators to target key neural circuits.

Draig Therapeutics develops therapies to restore brain health for patients with neuropsychiatric disorders.

Draig Therapeutics protects the privacy and security of personal data.

Last updated: 05 March 2026 Website: https://draigtherapeutics.com/

Draig Therapeutics collects and processes personal data on its website and acts as the data controller.

Draig Therapeutics secures a $65 million Series B funding round led by Deep Track Capital to advance its AMPA and GABAA receptor modulators for neuropsychiatric disorders. The round includes participation from Janus Henderson Investors and Marshall Wace. The oversubscribed financing aims to accelerate development of these highly specific compounds targeting neurological conditions.

Jul 2026SV Health InvestorsNews article

Draig Pharmaceuticals secures $65 million in Series B funding to advance mid-stage clinical trials of a candidate it describes as having 'best-in-disease' potential for treating major depressive disorder. The capital will accelerate testing of its AMPA/GABA-targeting drug, positioning it as a leading contender in the depression therapeutics pipeline.

Jul 2026BioPharma DiveNews article

Draig Therapeutics names **Ivana Magovčević-Liebisch** as President and Chief Executive Officer. She brings over 25 years of leadership experience in pharmaceuticals and biotechnology to the neuroscience-focused company. Her appointment follows a career marked by executive roles in drug development and therapeutic innovation.

Nov 2025SV Health InvestorsNews article

Draig Therapeutics secures US FDA clearance for its Investigational New Drug (IND) application, enabling a Phase 2 clinical trial of **DT-101**, a potential treatment for **major depressive disorder**. The therapy targets modulation of the **AMPA receptor**, aiming for efficacy without compromising safety. This milestone advances the company’s pipeline in psychiatric drug development.

Oct 2025SV Health InvestorsNews article